Taro Pharmaceutical Industries Ltd (TARO) Gross Profit Margin starting from the fourth quarter 2023 to fourth quarter 2022, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket
 


Taro Pharmaceutical Industries Ltd  (NYSE: TARO)


Taro Pharmaceutical Industries Ltd's Gross Profit Margin by quarter

Trends, Rankings, Statistics



TARO Gross Profit Margin (Mar 31 2023)
Q4
0
Q3
0
Q2
0
Q1
(Mar 31 2022)
Q4
Y / Y Revenue Change 2.07 %
Seq. Revenue Change -
Revenue In Millions $572.95
Gross Profit Margin 46.83 %
Gross Profit Margin Total Ranking # 1981
Gross Profit In Millions $268.32
Y / Y Gross Profit Change -8.46 %
Seq. Gross Profit Change -


Commenting fourth quarter 2023 Gross Profit Margin



Observing fourth quarter 2023 results within Major Pharmaceutical Preparations industry 139 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from to 1981.
Learn about Gross Margin
TARO's Gross Profit Margin fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 140
Healthcare Sector # 373
Overall # 1948

Gross Profit Margin Statistics
High Average Low
81.93 % 65.29 % 46.83 %
(Mar 31 2016)   (Mar 31 2023)




Other Gross Profit Margin Profitability Ratios
TARO's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
TARO's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for TARO's Competitors
Gross Profit Margin Profit Margin for Taro Pharmaceutical Industries Ltd's Suppliers
Gross Profit Margin Profit Margin for TARO's Customers

You may also want to know
TARO's Annual Growth Rates TARO's Profitability Ratios TARO's Asset Turnover Ratio TARO's Dividend Growth
TARO's Roe TARO's Valuation Ratios TARO's Financial Strength Ratios TARO's Gross Profit Growth
TARO's Roa TARO's Inventory Turnover Ratio TARO's Growth Rates TARO's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Gross Profit MarginMar 31 2023 MRQ Gross ProfitMar 31 2023 MRQ Revenue
Ptc Therapeutics inc   99.95 %$ 220.282  Millions$ 220.382  Millions
Intercept Pharmaceuticals inc   99.67 %$ 67.736  Millions$ 67.958  Millions
Macrogenics Inc   99.54 %$ 24.383  Millions$ 24.496  Millions
Ionis Pharmaceuticals Inc   98.97 %$ 129.181  Millions$ 130.524  Millions
Aurinia Pharmaceuticals Inc   98.78 %$ 33.988  Millions$ 34.409  Millions
Corcept Therapeutics Inc  98.69 %$ 104.268  Millions$ 105.654  Millions
Acadia Pharmaceuticals Inc   98.59 %$ 116.795  Millions$ 118.462  Millions
Deciphera Pharmaceuticals Inc   98.54 %$ 32.957  Millions$ 33.445  Millions
2seventy Bio Inc   98.46 %$ 40.980  Millions$ 41.621  Millions
Marinus Pharmaceuticals Inc   98.02 %$ 10.174  Millions$ 10.380  Millions
Innoviva Inc   97.96 %$ 76.936  Millions$ 78.536  Millions
Karyopharm Therapeutics Inc   96.51 %$ 37.347  Millions$ 38.698  Millions
Rigel Pharmaceuticals Inc  96.25 %$ 25.093  Millions$ 26.070  Millions
Zevra Therapeutics Inc   95.66 %$ 2.754  Millions$ 2.879  Millions
Bioxcel Therapeutics Inc   95.63 %$ 0.197  Millions$ 0.206  Millions
Gyre Therapeutics Inc   95.49 %$ 23.806  Millions$ 24.931  Millions
Clene Inc   95.33 %$ 0.102  Millions$ 0.107  Millions
Cti Biopharma Corp   94.92 %$ 22.892  Millions$ 24.116  Millions
Emmaus Life Sciences Inc   93.65 %$ 6.324  Millions$ 6.753  Millions
Regeneron Pharmaceuticals Inc   93.41 %$ 2,953.700  Millions$ 3,162.100  Millions
Spectrum Pharmaceuticals Inc   93.19 %$ 14.552  Millions$ 15.615  Millions
Sage Therapeutics Inc   93.02 %$ 3.064  Millions$ 3.294  Millions
Amylyx Pharmaceuticals Inc   92.60 %$ 66.145  Millions$ 71.428  Millions
Vanda Pharmaceuticals Inc   92.36 %$ 57.724  Millions$ 62.498  Millions
Axsome Therapeutics Inc   92.01 %$ 87.020  Millions$ 94.576  Millions
Amicus Therapeutics inc   91.95 %$ 79.328  Millions$ 86.270  Millions
Silo Pharma Inc  91.90 %$ 0.017  Millions$ 0.018  Millions
Lexaria Bioscience Corp   91.55 %$ 0.032  Millions$ 0.035  Millions
Travere Therapeutics Inc   91.01 %$ 51.868  Millions$ 56.993  Millions
Whitehawk Therapeutics Inc   90.98 %$ 5.338  Millions$ 5.867  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.